Etrabamine

Etrabamine
Clinical data
Other namesJL-14839; JL14839; 14.839JL; 6-Methylamino-4,5,6,7-tetrahydrobenzothiazole
Routes of
administration
Oral
Drug classDopamine receptor agonist; Dopamine D2 and D3 receptor agonist
ATC code
  • None
Identifiers
  • N-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-6-amine
CAS Number
PubChem CID
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H12N2S
Molar mass168.26 g·mol−1
3D model (JSmol)
  • CNC1CCC2=C(C1)SC=N2
  • InChI=1S/C8H12N2S/c1-9-6-2-3-7-8(4-6)11-5-10-7/h5-6,9H,2-4H2,1H3
  • Key:YDSVAKPJAOSZJA-UHFFFAOYSA-N

Etrabamine (INNTooltip International Nonproprietary Name; developmental code name JL-14839 or 14.839JL), also known as 6-methylamino-4,5,6,7-tetrahydrobenzothiazole, is a dopamine receptor agonist which was under development for the treatment of Parkinson's disease but was never marketed. It is taken orally.

The drug shows affinity for the dopamine D2 and D3 receptors (Ki = 2,620 nM and 300 nM, both for L-etrabamine). It acts as a dopamine D2 and D3 receptor agonist and does not appear to act as an agonist of the dopamine D1 receptor. Etrabamine produces stereotypy in rodents and to a greater extent than apomorphine. This can be blocked by the dopamine antagonists sulpiride, haloperidol, and pimozide. It reverses the hypolocomotion induced by the dopamine depleting agent reserpine in rodents. The drug reduces levels of dopamine metabolites in the striatum in rodents. It strongly suppresses prolactin levels in rodents.

The chemical synthesis of etrabamine has been described. The chemical structure of etrabamine was unlike that of other dopamine receptor agonists when it was first developed in the 1980s. Subsequently, pramipexole, a closely related derivative of etrabamine, was developed and introduced for the treatment of Parkinson's disease. Pramipexole shows 2.7- and 29-fold higher affinity for the dopamine D2 and D3 receptors than etrabamine, respectively. Various other analogues and derivatives of etrabamine besides pramipexole have also been developed.

Etrabamine was first described in the scientific literature in 1987. It was under development by Logeais. The drug reached phase 2 clinical trials prior to the discontinuation of its development in 1997. A close derivative known as pramipexole was first approved for medical use in 1997.

See also